Neumora Therapeutics (NMRA) Total Liabilities (2022 - 2026)

Neumora Therapeutics has reported Total Liabilities for 5 years, with the latest figure at $83.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Liabilities rose 193.11% year-over-year to $83.2 million; the trailing twelve-month figure through Mar 2026 stood at $83.2 million (up 193.11% YoY), and the FY2025 full-year result was $87.2 million, up 191.48% from the prior year.
• Total Liabilities for Q1 2026 stood at $83.2 million, down from $87.2 million in the prior quarter.
• The five-year high for Total Liabilities was $513.5 million in Q2 2023, with the low at $23.2 million in Q2 2024.
• Average Total Liabilities over 5 years is $126.5 million, with a median of $32.1 million recorded in 2023.
• Year-over-year, Total Liabilities sank 95.48% in 2024 and soared 193.11% in 2026.
• Tracing NMRA's Total Liabilities over 5 years: stood at $29.4 million in 2022, then dropped by 7.75% to $27.1 million in 2023, then grew by 10.28% to $29.9 million in 2024, then surged by 191.48% to $87.2 million in 2025, then slipped by 4.56% to $83.2 million in 2026.
• The last three Total Liabilities figures came in at $83.2 million (Q1 2026), $87.2 million (Q4 2025), and $45.7 million (Q3 2025), per Business Quant data.

Peer Comparison